Please login to the form below
drug pricing
This page shows the latest drug pricing news and features for those working in and with pharma, biotech and healthcare.
Democrats in the US agree plan to curb drug prices
House Democrats have added a measure to curb prescription drug costs to President Biden’s $1.85tr social safety net plan. ... Fixing prescription drug pricing has consistently been a top issue for Americans year after year, including the vast majority
Latest news
-
Pfizer, Sanofi and others set to increase US drug prices in 2021
Drug pricing will also be a focus of the incoming President-elect, Joe Biden, who has promised to reduce drug prices in the US. ... One key tenet of Biden’s drug pricing pledge is to allow Medicare to negotiate drug prices directly with pharma companies
-
Moderna looks to price COVID-19 vaccine at $50-$60 per course
Shines spotlight on pricing strategies for potential vaccines. COVID-19 vaccine frontrunner Moderna is allegedly looking to price its candidate at around $50-$60 per course, according to a report from ... According to the report, Moderna’s proposed
-
Lilly joins new Medicare scheme to reduce insulin prices
of-pocket drug costs.
-
FDA clears generic of Daraprim, the ‘poster drug’ for price-gouging
Phoenixus has resisted pressure to lower the price of the drug, and is reportedly haemorrhaging cash – a situation which will presumably only get worse once the generic is available. ... Gaming tactics include preventing generic drugmakers getting
-
Ex-Sandoz exec admits role in generic drug price-fixing plot
The two named products are clobetasol, an eczema and psoriasis treatment, and nystatin triamcinolone, an anti-fungal drug that also has a corticosteroid. ... Drug pricing is a particularly hot-topic among US politicians at the moment, and has snowballed
More from news
Approximately 72 fully matching, plus 196 partially matching documents found.
Latest Intelligence
-
Think fast, be different: succeeding at speed chess in 2021’s COVID-19 world
While certain stigmas about Big Pharma exist (eg, drug pricing), the companies’ names are well known and generally trusted by HCPs and consumers.
-
The search for effective drug treatments for COVID-19
What are the specific challenges of getting scientific consensus during a rapidly developing drug process in the midst of a global pandemic? ... How does pricing for the drug in the EU compare to pricing in the US?
-
Eliminating pharmaceutical rebates, is this déjà vu?
By Andrew Parece and Matthew Majewski. Eliminating pharmacy benefit manager (PBM) rebates has been proposed to address several healthcare issues associated with pharmaceutical pricing (eg, increasing patient prescription drug costs) but ... Due to
-
The impact of COVID-19 on clinical trials
Based on our discussions with venture capitalists, many anticipate potentially severe cash flow issues for drug developers. ... The impact of the pandemic on clinical trials is likely to be felt on a policy level, including in drug pricing negotiations.
-
Health trust in a COVID-19 world – a unique opportunity for pharma
Our team there hypothesised that this may be due to several highly publicised issues including Servier’s long-awaited trial over the safety of a weight loss drug, a large, monthslong ... hospital strike, increasing anti-vaccination sentiment and
More from intelligence
Approximately 7 fully matching, plus 40 partially matching documents found.
Latest appointments
-
New faces at Lucid Group and ZPB Associates
Most recently, she worked in the consultancy’s rare diseases division, where is provided crisis management support in pricing/access barriers for an orphan drug.
-
Pfizer’s Emms takes up ABPI presidency
Emms is no stranger to these issues, having served on the ABPI board and taken part in the negotiations over the future of drug pricing in the UK. ... He has not been afraid to criticise the outcomes of these discussions too, saying in November that the
-
Bayer's Martin Hesse moves to Daiichi Sankyo Europe
Commenting on the environment in which he starts at Daiichi, Hesse said securing the company's profitability and competitiveness in the light of drug pricing interventions will a major challenge.
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
Precision medicine with precision management and precision pricing; ensuring affordability in the cell and gene therapy era
drug pricing?”. ... fact that it falls into the drug budget in one fell swoop is a problem for payers.
-
OPEN Health
Precision medicine with precision management and precision pricing; ensuring affordability in the cell and gene therapy era. ... drug pricing?”.
-
Pricing's Point Man
In the wake of the publication of the second edition of 'The Price of Global Health', Ed Schoonveld talks to William Looney. Pharm Exec Editor-in-Chief William Looney talks to Ed Schoonveld about the key policy and management issues around market
-
Turkey: Identifying the Growth Drivers
This sector is dominated by pro-innovative drug prescribing physicians as well as a patient population who is willing to pay for a higher “quality” healthcare. ... Overall, while the public sector is characterised today byaggressive drug pricing
-
Article: The Colombia Conundrum
An essential drug list (‘POS – Plan Obligatorio de Salud’) is drawn up to cover the medicines to which Colombians are entitled under the EPS. ... drug pricing, as well as a streamlining of the essential drug list to remove some of the higher cost
More from PMHub
Approximately 3 fully matching, plus 6 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- AstraZeneca and Innate Pharma to end study on immuno-oncology drug monalizumab
- AstraZeneca and MSD’s breast cancer drug Lynparza receives EC approval
- Regeneron terminates four clinical trials of its COVID-19 antibody cocktail REGEN-COV
- Roche’s Tecentriq demonstrates positive phase 3 results as a subcutaneous injection
- Gilead announces positive Biktarvy data for HIV and hepatitis B
- Janssen announces positive results supporting Rybrevant and lazertinib combination treatment for NSCLC
- Medscape Education Receives Joint Accreditation with Commendation to Deliver Continuing Education for Healthcare Providers
- Amgen acquires ChemoCentryx in $3.7bn cash deal
- Gilead Sciences set to acquire MiroBio in deal worth over $400m
- NHS England to roll out continuous glucose monitors to all those with type 1 diabetes
- Sanofi and Innovent Biologics to develop oncology drugs for patients in China
- WHO launches funding appeal for greater Horn of Africa prompted by food crisis
PMHub
Wilmington Healthcare
A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...
Latest intelligence
- Animation: Living With
- The journey from the patient's perspective...
- Achieving communication excellence by targeting the right channel at the right time
- By Danny Buckland...
- 6 trends shaping the future of personalized medicine
- Senior Consultant Leah Carlisle explores the key trends discussed at the 16th annual Personalized Medicine Conference, providing expert analysis and key recommendations for biopharmaceutical innovators....
